Prosigna Breast Cancer Prognostic Gene Signature
Breast cancer is the most prevalent cancer in women, accounting for nearly one out of every ten new cancer diagnoses each year. It is the world's second most common cause of cancer death among women. Breast cancer is always evolving silently. So, patients discover their disease during their routine screening or accidentally discover a breast lump, change of breast shape or size, or nipple discharge. Breast cancer most of the time is triggered by certain genes which are either mutated or inherited. Prosigna Breast Cancer Prognostic Gene Signature Assay is one of the diagnostic procedures that use advanced genomic technology and also provides a clue to patient’s prognosis. It is an in vitro diagnostic assay that assesses a patient's risk of distant recurrence by analyzing the triggering gene expression profile of cells present in breast tissue.
The test examines the activity of 50 genes known as the prediction analysis of microarray 50 (PAM50) gene signature, as well as clinical and pathological features, and can provide a prognostic score to a hormone-receptor positive early breast cancer patient. The score helps physician by indicating the likelihood of cancer recurrence in the next 10 years and better treatment of breast cancer. Risk of recurrence (ROR) is stratified into low (10-year distant recurrence < 10%), intermediate (10-year distant recurrence 10–20%) and high scores (10-year distant recurrence >20%). Prosigna assay results are reported as a Prosgina score from 0 to 100: node-negative cancers are classified as low (0-40), intermediate (41-60), or high (61-100) risk and node-positive cancers are classified as low (0-40) or high (41-100) risk. The assay also aids classify breast tumors into five distinct subtypes: Luminal A, Luminal B, Basal, Her2-enriched, and normal-like.
- Evaluating long-term prognostic value of PAM50 subtypes in the ER/Her2− subgroup
- Prognosis about the risk of late distant recurrence in patients with ER tumors after 5 year of endocrine therapy
- To validate prognostic risk of recurrence (ROR) score to categorize patient’s as low, intermediate or high risk and predicts the probability of distance recurrence over 10 years
- To recommend for adjuvant therapy in postmenopausal patients with early-stage (stage I, II, or IIIa) breast cancer having node-neg/pos, ER-positive, HER2- negative disease
- To assess the appropriateness of chemotherapy in the adjuvant setting in patients with early-stage breast cancer whose initial presentation did not suggest a need for chemotherapy
Risk classification is provided to allow interpretation of the Prosigna Score by using cutoffs related to clinical outcome in tested patient populations.
Risk classification by Prosigna Score range and nodal status
Nodal Status Prosigna Score Range Risk Classification
Node-Negative
- 0–40 Low
- 41–60 Intermediate
- 61–100 High
Node-Positive (1–3 nodes)
- 0–40 Low
- 41–100 High
Recurrence score <10% - Low risk and the benefit of chemotherapy is less valuable than the side effect
Recurrence score 10% - 20% - Intermediate risk and the benefit of chemotherapy is more valuable than the side effect
Recurrence score >20 - High risk and the benefit of chemotherapy is greater than the side effect
| Parameter | Description |
|---|---|
| Prosigna Score | Integer value on a 0–100 scale |
| Risk Category (Node-Negative) | Low, Intermediate, High |
| Risk Category (1–3 Positive Nodes) | Low, High |
FFPE (Formalin-fixed paraffin-embedded) tumor tissue.
Stability
- Fix tissue stable at room temperature and refrigerator for a longer duration.
- Breast Cancer Res Treat. 2021 Jul;188(1):141-147. [PMID: 33860387]
- Journal of Clinical Oncology 2009, 27(8): 1160–1167. [PMID: 19204204]
- Curr Med Res Opin. 2015 Jun;31(6):1129-37. [PMID: 25851308]
- Breast Cancer Res Treat. 2020; 179(1): 197–206. [PMID: 31542876]
- Front Med (Lausanne). 2018 Sep 4;5:248. [PMID: 30234119]
- Breast Cancer Res. 2018 Jul 27;20(1):79. [PMID: 30053900]
- Nature Biotechnology 2008; 26: 317–25. [PMID: 18278033]
- Bland KI, Copeland EM, Klimberg VS, Gradishar WJ. The Breast: Comprehensive Management of Benign and Malignant Diseases.5th ed Elsevier Health Sciences; 2009 Jun 29.